GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma
GPX2 overexpression indicates poor prognosis in patients with hepatocellular carcinoma
复制标题
GPX2过表达提示肝细胞癌患者预后不良
DOI：
10.1177/1010428317700410
复制
发表时间：
2017-06-21
期刊：
影响因子：
--
通讯作者：
Li, Pin-dong
中科院分区：
文献类型：
--
作者：
Liu, Ting;Kan, Xue-feng;Li, Pin-dong
谷胱甘肽过氧化物酶2在多种肿瘤的发生发展中起重要作用，但对肝细胞癌的预后却知之甚少。采用免疫组织化学方法检测肝细胞癌组织中谷胱甘肽过氧化物酶2的表达。分析谷胱甘肽过氧化物酶2的表达与临床病理及预后的关系。谷胱甘肽过氧化物酶2的过度表达与甲胎蛋白水平、肿瘤较大、BCLC分期和肿瘤复发有关。Kaplan-Meier分析显示谷胱甘肽过氧化物酶2是总生存期和复发时间的独立预测因子。在按肿瘤大小、分化、肿瘤淋巴结转移和BCLC分期分层的患者亚组中，谷胱甘肽过氧化物酶2的过度表达与预后不良相关。此外，分层分析显示，谷胱甘肽过氧化物酶2高表达的I期肿瘤转移患者预后比低表达的患者差。此外，联合检测谷胱甘肽过氧化物酶2和甲胎蛋白与肝细胞癌的预后有关。结论：谷胱甘肽过氧化物酶2过度表达导致肝细胞癌患者预后不良，有助于识别高危肝细胞癌患者。
Glutathione peroxidase 2 has important role of tumor progression in lots of carcinomas, yet little is known about the prognosis of glutathione peroxidase 2 in hepatocellular carcinoma. Glutathione peroxidase 2 expression was assessed by immunohistochemistry in hepatocellular carcinoma tissues. The association between glutathione peroxidase 2 expression with clinicopathological/prognostic value was examined. Glutathione peroxidase 2 overexpression was correlated with alpha-fetoprotein level, larger tumor, BCLC stage, and tumor recurrence. Kaplan–Meier analysis showed that glutathione peroxidase 2 was an independent predictor for overall survival and time to recurrence. glutathione peroxidase 2 overexpression was correlated with poor prognosis in patient subgroups stratified by tumor size, differentiation, tumor–node–metastasis, and BCLC stage. Moreover, stratified analysis showed that tumor–node–metastasis stage-I patients with high glutathione peroxidase 2 expression had poor prognosis than those with low glutathione peroxidase 2 expression. Additionally, combination of glutathione peroxidase 2 and serum alpha-fetoprotein was correlated with prognosis in hepatocellular carcinoma. In conclusion, glutathione peroxidase 2 overexpression contributes to poor prognosis of hepatocellular carcinoma patients and helps to identify the high-risk hepatocellular carcinoma patients.